603456 九洲药业
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.76515.02018.65916.55012.820
总资产报酬率 ROA (%)2.05011.01212.32010.5287.870
投入资产回报率 ROIC (%)2.34313.19615.31312.7179.082

边际利润分析
销售毛利率 (%)34.04437.65634.66033.32737.506
营业利润率 (%)18.97921.28720.34718.54817.231
息税前利润/营业总收入 (%)17.69620.00618.68919.24420.457
净利润/营业总收入 (%)16.00418.67316.91415.60714.350

收益指标分析
经营活动净收益/利润总额(%)109.828105.670105.42098.12189.697
价值变动净收益/利润总额(%)-0.836-1.640-3.0038.0139.104
营业外收支净额/利润总额(%)-0.0160.413-0.371-1.194-1.388

偿债能力分析
流动比率 (X)2.7113.8121.8041.8091.406
速动比率 (X)2.0712.6290.8911.0030.689
资产负债率 (%)28.68621.36932.11934.98838.300
带息债务/全部投入资本 (%)17.2096.92911.70817.404--
股东权益/带息债务 (%)465.0531,301.104720.957456.889312.252
股东权益/负债合计 (%)246.569364.874208.389185.813160.946
利息保障倍数 (X)-13.826-14.610-11.81021.0235.908

营运能力分析
应收账款周转天数 (天)77.65453.23047.54162.7860.000
存货周转天数 (天)173.985208.092187.365189.4850.000